Changes in Gut Microbiota and Metabolites in Papillary Thyroid Carcinoma Patients Following Radioactive Iodine Therapy
Wanting Li,Feng Cheng,Jun Zhang,Caihong Li,Daijing Yu,Halimureti Simayijiang,Haiyan Liu,Sijin Li,Jiangwei Yan
DOI: https://doi.org/10.2147/ijgm.s433433
IF: 2.145
2023-10-03
International Journal of General Medicine
Abstract:Wanting Li, 1, &ast Feng Cheng, 1, &ast Jun Zhang, 1 Caihong Li, 2 Daijing Yu, 1 Halimureti Simayijiang, 1 Haiyan Liu, 2 Sijin Li, 2 Jiangwei Yan 1 1 Shanxi Key Laboratory of Forensic Medicine, Shanxi Medical University, Jinzhong, People's Republic of China; 2 Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jiangwei Yan; Sijin Li, Tel +86 03513985386 ; +86 03514639352, Email ; Purpose: Radioactive iodine therapy is administered through oral route, which is accumulated and absorbed in the intestine. However, its effects on the intestine remain unclear. In this study, we investigated the changes in the gut microbiota and metabolites following radioactive iodine therapy. Patients and Methods: A total of 76 stool samples from the same 38 patients were collected at the start of radioactive iodine therapy and three days following the therapy. Stool microbiota and metabolites were detected using 16S rRNA gene sequencing and liquid chromatography-mass spectrometry. Results: Enterobacteriales, Enterobacteriaceae and Escherichia-Shigella were elevated in most patients (27/38) following the therapy. The levels of 2-hydroxyundec-7-enoylcarnitine were significantly lower, whereas those of 5-dehydroavenasterol, butylisopropylamine, and salsoline-1-carboxylate were higher following the therapy. The relative abundance of Escherichia-Shigella was negatively correlated with 2-hydroxyundec-7-enoylcarnitine level (r 2 = − 0.661, P = 0.009). Functional pathways were predicted to be involved in amino acid and lipid metabolism following the therapy. Particularly, phenylalanine, linoleic acid, sphingolipid, purine, and alpha-linolenic acid metabolism were the main metabolic pathways. Conclusion: Gut microbiota was disturbed following radioactive iodine therapy, with increased Escherichia-Shigella . Processes associated with energy production seems to be impacted following the therapy, with significantly decreased 2-hydroxyundec-7-enoylcarnitine level. Meanwhile, some metabolites and functional pathways may have a positive effect on intestinal homeostasis, and may be related to the repair and promotion of gut recovery following the therapy. This study provides a basic foundation to explore how radioactive iodine affects gut microbiota and metabolites, and how gut function is regulated in response to radioactive iodine therapy. Keywords: radioactive iodine, gut microbiota, Escherichia-Shigella , metabolism, thyroid carcinoma Thyroid carcinoma was ranked as the fifth common malignancy in women from cancer statistics in 2020. 1 Differentiated thyroid carcinomas approximately account for 90% of all types of thyroid carcinoma. Patients with differentiated thyroid carcinomas had excellent survival outcomes, mainly due to the combination of surgery and appropriate radioactive iodine therapy. 2 Radioactive iodine therapy is proposed for the ablation of remnant thyroid tissue or iodine-avid metastases. 3 Radioactive iodine is administered through oral route, which is accumulated and absorbed in the intestine, thus it may affect the gut microbiota or metabolites. To date, few studies have reported changes in the gut microbiota or metabolites of patients with thyroid carcinoma following radioactive iodine therapy. Previous studies have indicated that gut microbiota is associated with thyroid carcinoma. 4–6 Another study investigated the dysbiosis of gut microbiota and metabolites in mice, six days following abdominal irradiation exposure. 7 In addition, gut bacterial compositions also changed in mice, seven days following total body radiation. 8 Given the paucity of studies on the gut microbiota or metabolites in thyroid carcinoma patients following radioactive iodine therapy, we report this research. The study protocol was approved by the Ethics Committee of the First Hospital of Shanxi Medical University (K-K176), in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants. The study was conducted in the First Hospital of Shanxi Medical University from November 2020 to October 2021. Inclusion criteria included thyroid carcinoma patients (above 18 years old) preparing for radioactive iodine therapy. Participants were excluded on condition that they had been diagnosed with other diseases, such as diabetes, hypertension, coronary heart disease, or gastrointestinal disease. Exclusion factors included taking antibi -Abstract Truncated-
medicine, general & internal